Kaan Uluer/iStock via Getty Images Note: All amounts discussed are in Canadian Dollars. Stock Prices refer to those on the TSX and not the OTC symbol. In May of this year, we switched to a Buy on Canadian Apartment Properties Real Estate Investment Trust (TSX:CAR.UN:CA) (“CAPREIT”) and acquired a chunk of shares. The REIT was hit with the same malaise that infected the entire Canadian sector. But unlike some distressed names, this one had no real issues, apart from a lack of investor patience. That pat ...

Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapyDemonstrates potential of stem cell memory T cells (TSCM), a key differentiator for Poseida's CAR-T programs SAN DIEGO, Sept. 4, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, highlighted new data from ...

SAN JOSE, Calif., Sept. 3, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the inventor of its ovarian cancer CAR-T technology, Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 15th Bie ...

Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company’s next-genera ...

Rost-9D/iStock via Getty ImagesAllogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotech company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. ALLO uses advanced gene-editing platforms like TALEN and CRISPR/Cas9 to engineer donor-derived T cells. These off-the-shelf treatments overcome the limitations of autologous therapies by targeting and killing malignant cells. The company’s robust pipeline covers hematologic malignancie ...

Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). GLPG5101 is an autologous CD19 CAR-T cell therapy product candidate produc ...

georgeclerk Summary We maintain our Hold rating on Canadian Apartment Properties Real Estate Investment Trust (TSX:CAR.UN:CA / OTC:CDPYF). While operational performance has remained solid, we believe there are far more attractive risk/return profiles within Canadian residential REITs, such as Northview Residential REIT. The current price's proximity to our NAV estimate leads us to believe that unit performance over the short term should follow NOI and FFO growth (i.e., sector performance). We need to se ...

HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has been awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the clinical investigation of MT-601 in patients with non-Hodgkin’ ...

Avis Budget Group, Inc. (CAR) reported lower-than-expected second-quarter 2024 results.The stock has increased 6.3% since its earnings release on Aug 5 despite the earnings and revenue miss.CAR’s earnings of 41 cents per share missed the Zacks Consensus Estimate by 84.2% and decreased 96.3% from the year-ago quarter’s actual. Total revenues of $3 billion missed the consensus estimate by 4% and decreased 2.4% on a year-over-year basis.Avis Budget’s shares have declined 47% in the past six months compared wit ...

Avis Budget Group, Inc. (NASDAQ:CAR) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants David Calabria - Senior Vice President, Corporate Finance and Treasurer Joseph Ferraro - President and Chief Executive Officer Izzy Martins - Executive Vice President and Chief Financial Officer Conference Call Participants Chris Woronka - Deutsche Bank Ryan Brinkman - JPMorgan John Babcock - Bank of America Lizzie Dove - Goldman Sachs Stephanie Moore - Jefferies Operator Greetings. Welcome t ...